🇺🇸 UMECLIDINIUM BROMIDE in United States

9,712 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthma — 1,857 reports (19.12%)
  2. Dyspnoea — 1,539 reports (15.85%)
  3. Wheezing — 1,197 reports (12.32%)
  4. Therapeutic Product Effect Incomplete — 1,057 reports (10.88%)
  5. Obstructive Airways Disorder — 783 reports (8.06%)
  6. Loss Of Personal Independence In Daily Activities — 782 reports (8.05%)
  7. Cough — 770 reports (7.93%)
  8. Condition Aggravated — 604 reports (6.22%)
  9. Chronic Obstructive Pulmonary Disease — 595 reports (6.13%)
  10. Drug Ineffective — 528 reports (5.44%)

Source database →

UMECLIDINIUM BROMIDE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is UMECLIDINIUM BROMIDE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for UMECLIDINIUM BROMIDE in United States?

Marketing authorisation holder not available in our data.